L-Adrenaline Clinical Trials

Size	Price	Qty
50mg	USD 147
1g	USD 670

Clinical Trials

Multiple clinical trials—encompassing Phase 2, Phase 3, and non-phase interventional studies—evaluate the clinical applications and physiological parameters of this intervention. These investigations target conditions including sepsis and septic shock, post-liver transplantation acute kidney injury, workplace-related stress and sleep disorders, and metabolic responses in healthy volunteers. Sponsored by academic institutions and healthcare organizations such as Mansoura University, Assistance Publique - Hôpitaux de Paris, National Taiwan Sport University, and Rigshospitalet Denmark, participant recruitment across these studies ranges from not yet recruiting to actively recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06302998	Not yet recruiting	Sepsis\|Septic Shock	Mansoura University	2024-06	Phase 2
NCT06344442	Not yet recruiting	Acute Kidney Injury Post Liver Transplantation	Assistance Publique - Hôpitaux de Paris	2024-05-05	Phase 3
NCT06381479	Recruiting	Stress\|Sleep Disorder	National Taiwan Sport University\|Bened Biomedical Co. Ltd.	2024-04-19	Not Applicable
NCT06334653	Not yet recruiting	Healthy Volunteers Only\|Energy Metabolism	Helga Ellingsgaard\|Rigshospitalet Denmark	2024-04-09	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the L-Adrenaline product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

L-Adrenaline binds directly to alpha- and beta-adrenergic receptors, triggering downstream G-protein-coupled signaling pathways that regulate intracellular cyclic AMP accumulation and vascular smooth muscle tone. This signaling cascade mediates vascular constriction, enhanced myocardial contractility, and metabolic substrate mobilization, providing critical therapeutic relevance in restoring systemic perfusion during septic shock and modulating metabolic energy expenditure.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).